Microsomal Triglyceride Transfer Protein (MTP) Inhibitor

Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC₅₀ of 8 nM in vitro.

Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia.

SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC₅₀ of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia.

LAB687 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC₅₀ of 0.9 nM for apolipoprotein B (apoB) secretion in HepG2 cells. LAB687 also acts as a Smoothened (Smo) antagonist, with IC₅₀ values of 2.48 μM and 3.42 μM against mouse and human Smo receptors, respectively. LAB687 reduces triglyceride and low-density lipoprotein cholesterol (LDL-C) levels, and inhibits the Hedgehog signaling pathway. LAB687 can be used in studies related to Hedgehog-dependent cancers.

Usistapide (JNJ-16269110) is a microsomal triglyceride transfer protein (MTP) inhibitor. Usistapide is promising for research of obesity.

Lomitapide-d₄ (AEGR-733-d₄) is deuterium labeled Lomitapide. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC₅₀ of 8 nM in vitro.

Lomitapide (Standard) is the analytical standard of Lomitapide. This product is intended for research and analytical applications. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.

SLX-4090 (Standard) is the analytical standard of SLX-4090 (HY-106011). This product is intended for research and analytical applications. SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein (MTP) inhibitor with an IC₅₀ of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia.

Granotapide is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces the absorption of cholesterol and triglycerides by inhibiting MTP. Granotapide can be used in the research of coronary artery disease, obesity, diabetes mellitus and hypertension.